Allena Pharmaceuticals

Super Nova Resources, Inc. engages in the provision of video communication services. It provides GreenLink Video Assistance and Point-of-Decision Systems through its subsidiary. It offers live, real-time, and bi-directional personal video communication between customers and customer service representatives stationed in centralized video command centers. The company was founded in 1965 and is headquartered in Corona, CA.

The stock price of Allena Pharmaceuticals Inc (NASDAQ: ALNA) increased by over 20% during intraday trading today. This is why it happened.

ALNA Stock: Why The Price Surged Today

- Novel oral therapeutic candidate ALLN-346 targets uric acid in the intestinal tract -

Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout and Advanced Chronic Kidney Disease

NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today reported financial results for the second quarter ended June 30, 2021 and highlighted recent corporate progress.

Allena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate Progress

NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in the upcoming 12th Annual Wedbush PacGrow Healthcare Conference on August 10th – August 11th, 2021.

Allena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference

NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the granting of inducement awards to two new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were made as a material inducement to each employee's entry into employment with the Company.

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

The stock price of Allena Pharmaceuticals Inc (NASDAQ: ALNA) fell by 35.04%. This is why it happened.

ALNA Stock Fell 35.04%: Why It Happened

Allena Pharmaceuticals Inc (NASDAQ: ALNA) has announced a registered direct offering of 21.3 million shares and warrants to purchase up to 10.7 million shares at $1.311. With gross proceeds of $28 million, the offering will close by July 16.

Allena Pharma Stock Under Pressure After Equity Raise Of $28M

NEWTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has entered into definitive agreements with several healthcare-focused institutional and accredited investors for the purchase and sale of 21,357,744 shares of the Company's common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 10,678,872 shares of the Company's common stock, at a purchase price of $1.311 per share of common stock (or common stock equivalent) and associated warrant, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about July 16, 2021, subject to the satisfaction of customary closing conditions.

Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

NEWTON, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., President and Chief Executive Officer, will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference. Management will also be available for 1x1 meetings on July 13-14, 2021. Details for the presentation are below:

Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference

Webinar Scheduled for Wednesday, June 16th @ 12 pm EDT Webinar Scheduled for Wednesday, June 16th @ 12 pm EDT

Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients with Chronic Kidney Disease

Allied Healthcare Products

China Xiangtai Food Co Ltd

Reliance Global Group

Trinity Biotech Plc

Looking for penny stocks to buy in May 2021? Here's some watchlist inspiration The post Top Penny Stocks For Your May Watchlist?

Top Penny Stocks For Your May Watchlist? Check These 5 Out

Allena Pharmaceuticals (ALNA) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: Allena Pharmaceuticals (ALNA)

-- Enrollment ongoing in Phase 3 URIROX-2 clinical trial of reloxaliase; interim analysis expected 2Q or 3Q 2022 -- -- Enrolling healthy volunteers in Phase 1b MAD study of ALLN-346; initial data expected 3Q 2021 -- -- On-track to initiate Phase 2a program for ALLN-346 in 3Q 2021; initial data expected 4Q 2021 -- -- Company to host KOL webinar on the unmet need in gout and potential for ALLN-346 on June 16, 2021 -- NEWTON, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today reported financial results for the first quarter ended March 31, 2021 and provided a business update.

Allena Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

NEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Mark J. Fitzpatrick to its board of directors.

Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors

-- Reloxaliase continues to progress through ongoing pivotal Phase 3 URIROX-2 trial for enteric hyperoxaluria -- -- ALLN-346 poised to enter Phase 1 multiple-ascending dose and Phase 2a trials for hyperuricemia and gout --

Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

NEWTON, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in two upcoming investor conferences in March:

Allena Pharmaceuticals to Present at Upcoming Investor Conferences in March

-- Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) -- -- Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) --

Allena Pharmaceuticals Appoints Richard D. Katz, M.D.

Is (ALNA) Outperforming Other Medical Stocks This Year?

Has Allena Pharmaceuticals (ALNA) Outpaced Other Medical Stocks This Year?

Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Allena Pharmaceuticals, Inc. (ALNA) Moves to Buy: Rationale Behind the Upgrade

NEWTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in two upcoming investor conferences in January:

Allena Pharmaceuticals to Present at Upcoming Investor Conferences in January

Regulus Therapeutics

Billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 Asset Management, established a 14.37% stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) and a 7.96% position in Allena Pharmaceuticals Inc. (NASDAQ:ALNA) on Dec. 4.

Steven Cohen Boots Health Care Exposure With 2 Biotech Stocks

NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 10,400,000 shares of common stock of the Company, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, 2020, subject to satisfaction of customary closing conditions.

Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million

NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 8,000,000 shares of common stock of the Company, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, 2020, subject to satisfaction of customary closing conditions.

Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering

NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of David J. Clark, M.D., M.R.C.P, as Chief Medical Officer, effective immediately. Dr. Clark succeeds Annamaria Kausz, M.D., who will transition to supporting the company in an advisory capacity.

Allena Pharmaceuticals Announces Appointment of David J. Clark, M.D.

-- Single-Ascending Doses of ALLN-346 Oral Enzyme Well-Tolerated -- -- Non- A bsorption o f ALLN-346 Demonstrated -- -- Advancing to Phase 1b Multiple - Ascending Dose Study and Phase 2 Proof-of-Concept Trial ; Initial Data from Both Studies Expected in Second Half of 2021 -- NEWTON, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced clinical data from its Phase 1 trial of ALLN-346 in healthy volunteers. ALLN-346 is an investigational, orally administered, novel urate-degrading enzyme that has been designed for activity and stability in the gastrointestinal (GI) tract, and is intended for the treatment of hyperuricemia in patients with gout and chronic kidney disease (CKD).

News for Allena Pharmaceuticals Stock (ALNA)